Literature DB >> 21866962

Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Corban G Rivera1, Elena V Rosca, Niranjan B Pandey, Jacob E Koskimaki, Joel S Bader, Aleksander S Popel.   

Abstract

Angiogenesis is the growth of new blood vessels from existing vasculature. Excessive vascularization is associated with a number of diseases including cancer. Antiangiogenic therapies have the potential to stunt cancer progression. Peptides derived from type IV collagen are potent inhibitors of angiogenesis. We wanted to gain a better understanding of collagen IV structure-activity relationships using a ligand-based approach. We developed novel peptide-specific QSAR models to study the activity of the peptides in endothelial cell proliferation, migration, and adhesion inhibition assays. We found that the models produced quantitatively accurate predictions of activity and provided insight into collagen IV derived peptide structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21866962      PMCID: PMC3195544          DOI: 10.1021/jm200114f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.

Authors:  Y Maeshima; M Manfredi; C Reimer; K A Holthaus; H Hopfer; B R Chandamuri; S Kharbanda; R Kalluri
Journal:  J Biol Chem       Date:  2001-02-07       Impact factor: 5.157

2.  Additive method for the prediction of protein-peptide binding affinity. Application to the MHC class I molecule HLA-A*0201.

Authors:  Irini A Doytchinova; Martin J Blythe; Darren R Flower
Journal:  J Proteome Res       Date:  2002 May-Jun       Impact factor: 4.466

3.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

4.  Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Int J Biochem Cell Biol       Date:  2007-07-30       Impact factor: 5.085

Review 5.  The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art.

Authors:  Irina Arnaoutova; Jay George; Hynda K Kleinman; Gabriel Benton
Journal:  Angiogenesis       Date:  2009-04-28       Impact factor: 9.596

6.  New descriptors of amino acids and their application to peptide QSAR study.

Authors:  Zhi-hua Lin; Hai-xia Long; Zhu Bo; Yuan-qiang Wang; Yu-zhang Wu
Journal:  Peptides       Date:  2008-06-18       Impact factor: 3.750

7.  Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.

Authors:  Yohei Maeshima; Akulapalli Sudhakar; Julie C Lively; Kohjiro Ueki; Surender Kharbanda; C Ronald Kahn; Nahum Sonenberg; Richard O Hynes; Raghu Kalluri
Journal:  Science       Date:  2002-01-04       Impact factor: 47.728

8.  Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.

Authors:  Hans Petter Eikesdal; Hikaru Sugimoto; Gabriel Birrane; Yohei Maeshima; Vesselina G Cooke; Mark Kieran; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

9.  A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  J Biol Chem       Date:  2004-07-12       Impact factor: 5.157

Review 10.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

View more
  10 in total

1.  Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides.

Authors:  Elena V Rosca; Jacob E Koskimaki; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel
Journal:  Chem Biol Drug Des       Date:  2012-04-27       Impact factor: 2.817

2.  Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.

Authors:  Jacob E Koskimaki; Esak Lee; William Chen; Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Aleksander S Popel
Journal:  Angiogenesis       Date:  2012-09-29       Impact factor: 9.596

3.  Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.

Authors:  Elena Victoria Rosca; Bachchu Lal; Jacob E Koskimaki; Aleksander S Popel; John Laterra
Journal:  Anticancer Drugs       Date:  2012-08       Impact factor: 2.248

Review 4.  Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Authors:  Stacey D Finley; Liang-Hui Chu; Aleksander S Popel
Journal:  Drug Discov Today       Date:  2014-10-05       Impact factor: 7.851

5.  A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.

Authors:  Elena V Rosca; Marie-France Penet; Noriko Mori; Jacob E Koskimaki; Esak Lee; Niranjan B Pandey; Zaver M Bhujwalla; Aleksander S Popel
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

6.  Inhibition of breast cancer growth and metastasis by a biomimetic peptide.

Authors:  Esak Lee; Seung Jae Lee; Jacob E Koskimaki; Zheyi Han; Niranjan B Pandey; Aleksander S Popel
Journal:  Sci Rep       Date:  2014-11-20       Impact factor: 4.379

7.  An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.

Authors:  Jian Xu; Xiu-Jun Liu; Liang Li; Sheng-Hua Zhang; Yi Li; Rui-Juan Gao; Yong-Su Zhen
Journal:  Oncotarget       Date:  2015-09-22

Review 8.  Computer-aided design of amino acid-based therapeutics: a review.

Authors:  Tayebeh Farhadi; Seyed MohammadReza Hashemian
Journal:  Drug Des Devel Ther       Date:  2018-05-14       Impact factor: 4.162

9.  MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells.

Authors:  Xiao-Dong Wu; Ting Guo; Li Liu; Chao Wang; Kun Zhang; Han-Qiang Liu; Feng Wang; Wen-Dong Bai; Meng-Yao Zhang
Journal:  Oncotarget       Date:  2017-07-22

10.  Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.

Authors:  Xiao Yu Wu; Hao Xu; Zhen Feng Wu; Che Chen; Jia Yun Liu; Guan Nan Wu; Xue Quan Yao; Fu Kun Liu; Gang Li; Liang Shen
Journal:  Oncotarget       Date:  2015-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.